In our latest interview, EU-OPENSCREEN Director General Philip Gribbon talks about his new role as SLAS President, the future of drug discovery, and why collaboration and AI are key to driving…
An African and European research consortium receives €1.5 million from the European Union and additional resources from the Swiss government to support the accumulation of knowledge, skills and…
EU-OPENSCREEN held its biannual Assembly of Members (AoM) meeting for the first time outside of Germany. The meeting in Riga, Latvia, kicks off a new initiative to host future meetings in different…
Together with our partner sites, we encourage researchers working on the neuroscience of pain to build transnational consortia with us and apply for the ERA-Net NEURON Joint Transnational Call 2025.
The EU-OPENSCREEN team is excited to highlight that this week's SLAS conference in San Diego, California, will see Phil Gribbon becoming the SLAS President for 2025. The SLAS is the largest…
EU-OPENSCREEN co-organises the next International Helmholtz Drug Discovery Conference 2025 (HDDC2025) at the MDC.C in Berlin. The focus of HDDC2025 is RNA as drug and drug target, Novel cardiovascular…
To advance access to cutting-edge facilities for chemical biology and early drug discovery, EU-OPENSCREEN depends on the active engagement and initiative of all partner sites. We are therefore pleased…
Three institutions have joined our consortium as official Chemoproteomics and Spatial Mass Spectrometry (MS)-Based Omics partner sites, enhancing the services we can offer to the research community in…
Our Lead Data Scientist Christopher Schmied and his collaborator Helena Jambor (Hochschule für Technik und Wirtschaft Graubünden, Chur, Schweiz; Technische Universität Dresden) have been granted the…
